Date | Price Target | Rating | Analyst |
---|---|---|---|
11/24/2021 | $26.00 | Buy | HC Wainwright & Co. |
4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
10-Q - Ocuphire Pharma, Inc. (0001228627) (Filer)
8-K - Ocuphire Pharma, Inc. (0001228627) (Filer)
8-K - Ocuphire Pharma, Inc. (0001228627) (Filer)
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today. George Magrath, M.D. M.B.A, M.S. CEO commented, "As the biology of Ref-
FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of Joseph (Joe) K. Schachle, M.B.A., into the newly created role of Chief Operating Officer, effective today. "Joe is a highly accomplished pharmaceutical executive, and we are thrilled to welcome him to Ocuphire as Chief Operating Officer," said Dr. George Magrath, CEO of Ocuphire. "His appointment is part of a broader strategic initiative to expand our senior team as we plan for adv
FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and member of the Board of Directors, effective today. Dr. Magrath succeeds Rick Rodgers, M.B.A., Interim Chief Executive Officer and President since April 2023. Mr. Rodgers will remain on the company's Board of Directors. "We are thrilled to have Dr. Magrath, a highly accomplished pharmaceutical executive with e
Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form
SC 13G/A - Ocuphire Pharma, Inc. (0001228627) (Subject)
SC 13G - Ocuphire Pharma, Inc. (0001228627) (Subject)
SC 13G/A - Ocuphire Pharma, Inc. (0001228627) (Subject)
CEO to participate in ARVO SIG panel on oral medications for retinal diseasesZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting
The Dow Jones index closed higher by 0.2% on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Bespoke Extracts The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod bought a total of 2,000 shares at an average price of $0.13. To acquire these shares, it cost around $268. What's Happening: The company’s stock lost around 48% over the pas
HC Wainwright & Co. initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $26.00
Alliance Global Partners initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $25.00
JonesTrading initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $20.00
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants. Pr
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants. Pr
VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2025 Preparatory Steps Towards Phase 2/3 with APX3330 in Diabetic Retinopathy are Ongoing Cash Position of $41.4 million Provides Runway Anticipated into mid-2025 FARMINGTON HILLS, Mich., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive e
4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2025 Preparatory Steps Towards Phase 2/3 with APX3330 in Diabetic Retinopathy are Ongoing Cash Position of $41.4 million Provides Runway Anticipated into mid-2025 FARMINGTON HILLS, Mich., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive e
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™," said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire. "We have been engaged in productive dialogue with the U.S. Food and Drug Administration (FDA) with respect to our submitted Special Protocol Assessmen
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. "Ocuphire had a successful 2023, with notable achievements on the regulatory and development fronts, paving the way for further progress in the year ahead," said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire. "Our strategic focus is on the advancement of our retina pipeline, and we are preparing